Semaglutide improved cognition, reduced amyloid plaques and tau phosphorylation, decreased neuroinflammation, and restored oxytocin levels in both Alzheimer's mice and human brain organoids.
Oxytocin restoredSemaglutide unexpectedly increased brain oxytocin levels alongside reducing amyloid plaques and improving cognition in Alzheimer's models
What the researchers found
Semaglutide reduced amyloid plaques, p-Tau, and neuroinflammatory markers (GFAP, Iba1) while restoring oxytocin levels in both APP/PS1 mice (with improved cognition) and human AD brain organoids.
Why it matters
Alzheimer's has no effective treatment. Semaglutide is already FDA-approved and taken by millions. If it truly protects the brain, it could be repurposed for AD much faster than developing a new drug — and the oxytocin restoration suggests a novel mechanism beyond simple anti-inflammation.
The numbers in context
Semaglutide improved learning and memory in behavioral tests, reduced amyloid plaque deposition, and restored oxytocin levels in APP/PS1 mice.
How the study worked
APP/PS1 transgenic Alzheimer's mice: behavioral testing (learning and memory), immunohistochemistry for amyloid plaques, GFAP, Iba1, and oxytocin. Human AD brain organoids: Aβ, p-Tau, GFAP, and oxytocin measurements after semaglutide treatment.
Who was studied
APP/PS1 Alzheimer's mice and human brain organoid models treated with semaglutide
What this study cannot tell us
APP/PS1 mice model only familial Alzheimer's (a minority of cases). Human brain organoids lack full brain architecture and connectivity. The mechanism linking semaglutide to oxytocin restoration is not fully explained. Clinical trials in AD patients are needed.
How to read the evidence
Moderate evidence: dual-model preclinical study (mice + human organoids) with consistent results, but no clinical data in AD patients.
When this study was published
Published in 2024 in Biomedicine & Pharmacotherapy. Adds to growing evidence for GLP-1 drugs in neurodegeneration.
The bigger picture
GLP-1 drugs are being investigated for Alzheimer's in clinical trials. This study adds an unexpected finding — semaglutide restores oxytocin, a neuropeptide linked to social bonding, memory, and neuroprotection. The dual peptide story (GLP-1 drug restoring oxytocin) suggests GLP-1 agonists may have broader neuroprotective mechanisms than previously understood.
Questions still open
- How does semaglutide increase brain oxytocin — through GLP-1R signaling, anti-inflammatory effects, or another mechanism?
- Do Alzheimer's patients taking semaglutide for diabetes show slower cognitive decline in clinical data?
- Could combining semaglutide with intranasal oxytocin provide synergistic neuroprotection in AD?
Common questions
Could semaglutide prevent or treat Alzheimer's?
Why did semaglutide increase oxytocin?
Read the original research
Semaglutide ameliorates Alzheimer's disease and restores oxytocin in APP/PS1 mice and human brain organoid models.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 180, 117540
Citation
Zhang, Yinbing; Tang, Cheng; He, Yao; Zhang, Yingqian; Li, Qinxi; Zhang, Ting; Zhao, Bangcheng; Tong, Aiping; Zhong, Qixing; Zhong, Zhihui. (2024). Semaglutide ameliorates Alzheimer's disease and restores oxytocin in APP/PS1 mice and human brain organoid models.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 180, 117540. https://doi.org/10.1016/j.biopha.2024.117540